| Identification | More | [Name]
N-Acetyl-L-leucine | [CAS]
1188-21-2 | [Synonyms]
2-(ACETYLAMINO)-4-METHYLPENTANOIC ACID
AC-DL-LEU-OH
ACETYL-DL-LEUCINE
ACETYL-DL-LEUCINE, N-
ACETYL-L-LEUCINE
AC-LEUCINE
AC-LEU-OH
AKOS BBS-00004735
IFLAB-BB F0777-0821
N-ACETYL-DL-LEU
N-ACETYL-DL-LEUCINE
N-ACETYL LEUCINE
N-ACETYL-L-LEUCINE
N-ALPHA-ACETYL-DL-LEUCINE
N-ALPHA-ACETYL-L-LEUCINE
(S)-2-ACETYLAMINO-4-METHYL-PENTANOIC ACID
(S)-N-Acetylleucine
Leucine, N-acetyl-, L-
L-Leucine, N-acetyl-
N-Acetyl-L-lenucine | [EINECS(EC#)]
214-706-3 | [Molecular Formula]
C8H15NO3 | [MDL Number]
MFCD00026498 | [Molecular Weight]
173.21 | [MOL File]
1188-21-2.mol |
| Chemical Properties | Back Directory | [Appearance]
White crystalline powder | [Melting point ]
187-190 °C(lit.)
| [alpha ]
-24.5 º (c=4, MeOH) | [Boiling point ]
303.86°C (rough estimate) | [density ]
1.1599 (rough estimate) | [refractive index ]
-22 ° (C=5, EtOH) | [storage temp. ]
−20°C
| [solubility ]
DMSO (Slightly), Ethanol (Slightly), Water (Slightly, Heated) | [form ]
Crystalline Powder | [pka]
3.67±0.10(Predicted) | [color ]
White | [Optical Rotation]
[α]25/D 23±3°, c = 2 in ethanol | [Water Solubility ]
0.81 g/100 mL (20 ºC) | [BRN ]
1724849 | [Major Application]
peptide synthesis | [InChI]
1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1 | [InChIKey]
WXNXCEHXYPACJF-ZETCQYMHSA-N | [SMILES]
CC(C)C[C@H](NC(C)=O)C(O)=O | [CAS DataBase Reference]
1188-21-2(CAS DataBase Reference) | [NIST Chemistry Reference]
L-leucine, n-acetyl-(1188-21-2) | [EPA Substance Registry System]
1188-21-2(EPA Substance) |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS07 | [Signal word ]
Warning | [Hazard statements ]
H319-H315-H335 | [Precautionary statements ]
P271-P261-P280 | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S24/25:Avoid contact with skin and eyes .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [TSCA ]
Yes | [HazardClass ]
IRRITANT | [HS Code ]
29241990 | [Storage Class]
11 - Combustible Solids |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder | [Uses]
N-Acetyl-L-(-)-leucine is used in the preparation of small molecule inhibitors of anti-apoptotic Bcl-2 family proteins. Also used in the preparation of amphiphilic copolymers involving hydrophobic amino acid and oligopeptide side chains for optical tumor imaging in vivo. | [Definition]
ChEBI: The N-acetyl derivative of L-leucine. | [reaction suitability]
reaction type: C-H Activation
reaction type: solution phase peptide synthesis
reagent type: catalyst
reaction type: Peptide Synthesis | [Pharmaceutical Applications]
N-acetyl-l-leucine (NALL) has shown therapeutic potential for neurodegenerative diseases, including in prodromal stages of Parkinson's disease (PD). Researches show that the therapeutic potential of NALL for PD by its protective effects on α-synuclein pathology and synaptic function in vulnerable dopaminergic neurons[1]. | [in vivo]
Levacetylleucine (60 mg/kg, i.v., administration on days 1, 2 and 3 for 15 days) decreases the postural imbalance scores and accelerates the course of postural compensation induced by UL in rats[3].
Levacetylleucine (100 mg/kg, oral gavage, administration daily for 28 days) attenuates cortical cell death afer traumatic brain injury (TBI) in N-Acetyl-L-leucine-treated TBI mouse cortices[4].
| Animal Model: | Male Sprague-Dawley rats (mean 400±20 g, age 3 months) after chemical UL[3] | | Dosage: | 60 mg/kg | | Administration: | i.v., 15 days | | Result: | Significantly decreased the postural imbalance scores on 7 day and accelerated the course of postural compensation by about 6 days in rats. |
| Animal Model: | C57/BL6 mice[4] | | Dosage: | 100 mg/kg | | Administration: | oral gavage, administration daily for 1-28 days | | Result: | Did not afect food intake and body weight in mice. |
| Animal Model: | N-Acetyl-L-leucine-treated TBI mouse cortices[4] | | Dosage: | 100 mg/kg | | Administration: | oral gavage, administration daily for 28 days | | Result: | Prevented cortical cell death which peaks at early time points (day 1) afer TBI in N-Acetyl-L-leucine-treated TBI mouse cortices. |
| [IC 50]
Human Endogenous Metabolite | [References]
[1] Song, P., Chen, C., Franchini, R., Duong, B., Wang, Y.-Z., Coukos, R., Xie, Z., Savas, J. N., Zhou, Y., Bertoldi, M., Surmeier, D. J., Parisiadou, L., & Krainc, D. (2026). N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in Parkinson's disease models. Journal of Clinical Investigation, 136 5. https://doi.org/10.1172/JCI196137
|
|
|